Last reviewed · How we verify
oral ramosetron
At a glance
| Generic name | oral ramosetron |
|---|---|
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Special Drug Use Surveillance of Irribow in Female Patients
- The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence (PHASE2, PHASE3)
- Ramosetron OD Tablet and Postdischarge Nausea and Vomiting (PHASE4)
- The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery (NA)
- A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (PHASE3)
- A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) (PHASE3)
- A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome (PHASE4)
- A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral ramosetron CI brief — competitive landscape report
- oral ramosetron updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI